To validate that the effects of rAAV-TRABID on NAFLD alleviation are mediated by Vps34, SAR405, a highly specific inhibitor of the PI3-kinase activity of VPS3458, was co-administrated with rAAV-TRABID (Fig. 8a). This evidence concerns the gene PIK3C3 and metabolic dysfunction-associated steatotic liver disease.